TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02054559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT05650203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
Description: 1. JS009 as Monotherapy in first cycle of dose escalation and as the triple combination therapy will be administered in subsequent cycles：JS009,18mg/60mg/180mg/600mg/1200mg, JS006, fixed dose 600mg, Toripalimab injection fixed dose 240mg,IV infusion, every 3 weeks (q3w).~2. Triple combination therapy in dose expansion：JS009, 1 or 2 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).~3. Triple combination therapy in indication expansion：JS009, 1 specific dose, with fixed dose of JS006 and Toripalimab Injection, IV infusion, every 3 weeks (q3w).
Study: NCT05560620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sleep Deprivation
Description: Participants will be randomized into either the sleep deprivation group or the control group, who will sleep regularly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: On Day 2 morning, after the sleep deprivation or sleeping, participants will be randomized into receiving caffeinated or de-caffeinated coffee, which they will be blinded to.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Caffeine
Description: De-caffeinated coffee

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Caffeine
Description: De-caffeinated coffee
Study: NCT04829071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit motor learning
Description: Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit motor learning
Description: Participants will walk on a treadmill that drives their right and left legs to move at two different speeds.
Study: NCT05465902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA COVID-19 vaccine (Moderna)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Viral Vector COVID-19 vaccine (AstraZeneca)
Description: 1dose, Intramuscular Injection
Study: NCT05868590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: Using two different toothpastes for removal of the dental plaque in children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste
Description: Using two different toothpastes for removal of the dental plaque in children.
Study: NCT06459700

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplements
Description: See arm/group description

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplements
Description: See arm/group description
Study: NCT06108011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lollipop
Description: sucking of lollipop after operation
Study: NCT05194332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP sonication to the amygdala
Description: LIFUP sonication to amygdala will be performed.
Study: NCT04739943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Monitoring
Description: Participants use a smartphone app for self monitoring of respiratory symptoms
Study: NCT05362448

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Frequency
Description: First, we will calculate for each patient and each frequency the amplitude therapeutic window (difference between therapeutic and side effect threshold). We will determine an optimal amplitude for each frequency that we will apply in the second part of the study.
Study: NCT05162404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Education Program
Description: The following topics are addressed in each module of the videos:~1. Understanding cancer and cancer treatment - including an understanding of stage, site of origin, metastases, treatment options, toxicities and anticipated outcomes.~2. Care coordination basics (CC: Communication) - including navigating care related to appointments, how to handle issues after-hours, and the expected roles of other healthcare providers (e.g., PCPs).~3. How to be a self-advocate (CC: Navigation and Operational) - including how to ask questions, being empowered to talk to your doctor, when a second opinion is needed, when to explore clinical trials, and how to best incorporate a caregiver into your treatment.
Study: NCT05969470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal fixation with short intramedullary nails
Description: Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a shorter intramedullary nail (defined as defined as less than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal fixation with long intramedullary nails
Description: Intramedullary nailing is a method of internal fixation used to treat fractures. An intramedullary nail is a metal rod forced into the marrow canal of a bone to stabilize and align fractures. Participants in this group will be fixed with a longer intramedullary nail (defined as greater than 2/3 of the patient's femur) for proximal femoral (impending) pathological fractures.
Study: NCT05588284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioJet device
Description: A device can be used for thrombus aspiration and thrombolysis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: anticoagulation alone
Description: a medicine for anticoagulation therapy
Study: NCT05720416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein supplementation
Description: protein supplementation for 16 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscle strength training
Description: muscle strength training for 16 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscle strength training
Description: muscle strength training for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: no intervention
Study: NCT00992862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Univasc® 15mg Tablets
Study: NCT05775419

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (4 courses)
Description: Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Concurrent chemotherapy (2 courses)
Description: Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
Study: NCT06183034

Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Calorie Diet
Description: Participants will receive a very low calorie diet as described in the arm/group
Study: NCT05032014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M9
Description: one times a day during the whole treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04249427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab Prefilled Syringe
Description: 140mg Erenumab, pre-filled syringe given by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, pre-filled syringe given by subcutaneous injection
Study: NCT04522219

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: Acquisition of contrast enhanced ultrasound. Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients
Study: NCT05562869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept 250 Milligram Intravenous Powder for Solution
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Study: NCT06319027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-Chelate
Description: Receive gadolinium-based contrast agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopy
Description: Undergo MR spectroscopy
Study: NCT05843422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% QY211 Gel or placebo
Description: QY211 Gel or placebo topical applied to skin
Study: NCT04519866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture
Description: After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above).
Study: NCT06319027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT05350020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef 100 MG Injection
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef 100 MG Injection
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial withinmarketing authorisations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100mg/ml
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100mg/ml
Description: Licensed medicine used in clinical practice. Preparations will be used unmodified in this trial within marketing authorisations.
Study: NCT06233604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
Study: NCT04608773

Intervention type: OTHER
Group type: OTHER
Intervention: Remineralizing Extreme Dry Mouth Spray with Xylitol
Description: oral hydrating spray

Intervention type: OTHER
Group type: OTHER
Intervention: Remineralizing Extreme Dry Mouth Spray with Xylitol
Description: oral hydrating spray

Intervention type: DEVICE
Group type: OTHER
Intervention: Alcohol-Free Moisturizing Dry Mouth Spray
Description: oral hydrating spray

Intervention type: DEVICE
Group type: OTHER
Intervention: Alcohol-Free Moisturizing Dry Mouth Spray
Description: oral hydrating spray
Study: NCT04812197

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen Collection(Punch Biopsy)
Description: Punch Biopsy of Skin
Study: NCT05539144

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Oropharyngeal mucosa
Description: Oropharyngeal mucosa was delineated as OARs and limiting its dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: oropharynx
Description: oropharynx was delineated as OARs and limiting its dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: oropharynx and oropharyngeal mucosa
Description: oropharynx and oropharyngeal mucosawere delineated as OARs and limiting its dose
Study: NCT06049576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrciaria dubia Prebiotic Supplement
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05930613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab (CIMZIA® ; TNF-α antagonist)
Description: 400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0.9 % solution)
Description: NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
Study: NCT06437782

Intervention type: OTHER
Intervention: Questionnaire completion
Description: HLQ (Health Literacy questionnaire) will be completed by all included patients once.

Intervention type: OTHER
Intervention: Questionnaire completion
Description: HLQ (Health Literacy questionnaire) will be completed by all included patients once.

Intervention type: OTHER
Intervention: Questionnaire completion
Description: HLQ (Health Literacy questionnaire) will be completed by all included patients once.
Study: NCT05562167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNO3
Description: 10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
Study: NCT05316623

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
Study: NCT06550089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
Study: NCT04966845

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of concentration on exhaled Carbon Monoxide
Description: exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of concentration on exhaled Carbon Monoxide
Description: exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of concentration on exhaled Carbon Monoxide
Description: exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]
Study: NCT05570773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peer support program
Description: Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: peer support program
Description: Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)